Dexcom
Dexcom, Inc., a leading player in the diabetes care industry, is headquartered in the United States. Founded in 1999, the company has pioneered continuous glucose monitoring (CGM) technology, significantly enhancing diabetes management for patients worldwide. With a strong presence in North America, Europe, and Asia, Dexcom focuses on developing innovative solutions that empower individuals to take control of their health. The company's flagship products, including the Dexcom G6 and G7 CGM systems, offer real-time glucose monitoring with exceptional accuracy and ease of use. These devices are distinguished by their ability to provide users with actionable insights, helping to prevent hypoglycaemic events and improve overall glycaemic control. Dexcom's commitment to innovation has solidified its position as a market leader, recognised for its contributions to diabetes management and patient care.
DitchCarbon Score
How does Dexcom's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Dexcom's score of 37 is higher than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Dexcom's reported carbon emissions
In 2023, Dexcom, Inc., headquartered in the United States, reported total carbon emissions of approximately 6,652,000,000 kg CO2e across all scopes. This includes 6,652,000,000 kg CO2e from Scope 1 emissions, which encompass direct emissions from owned or controlled sources, and 25,291,000 kg CO2e from Scope 2 emissions, related to indirect emissions from the generation of purchased electricity. Additionally, Scope 3 emissions, which cover all other indirect emissions, amounted to a significant 479,576,000,000 kg CO2e, primarily driven by business travel and waste generated in operations. Comparatively, in 2022, Dexcom's total emissions were about 4,768,000,000 kg CO2e for Scope 1, 13,610,000 kg CO2e for Scope 2, and 1,749,000,000 kg CO2e for Scope 3. This indicates a substantial increase in emissions, particularly in Scope 3, which reflects the complexities of managing indirect emissions in the healthcare equipment sector. Dexcom has committed to near-term climate targets, although specific reduction targets have not been disclosed. The company is actively engaged in sustainability initiatives, reflecting its commitment to addressing climate change within the healthcare equipment and supplies sector. However, it has not yet committed to a net-zero target. Overall, Dexcom's emissions data highlights the challenges faced by the healthcare sector in reducing carbon footprints, particularly in managing Scope 3 emissions, which often represent the largest share of total emissions.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 2,044,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
| Scope 2 | 9,371,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 1,257,000,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Dexcom is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
